Esparza-López José, Martínez-Aguilar Juan F, Ibarra-Sánchez María de J
Red de Apoyo a la Investigación (RAI), CIC-Universidad Nacional Autónoma de México.
Biochemistry Unit, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, México City, México.
Rev Invest Clin. 2019;71(6):369-380. doi: 10.24875/RIC.19002832.
Cancer is the second-leading cause of death in the world, accounting for one out of six deaths. Consequently, there is an urgent need for new and more effective therapeutic options as well as drug screening methods. Immortal, "stable" cancer cell lines have been employed since the past century to assess drug response but face several disadvantages. They often accumulate new genetic aberrations due to long-term culture and lack the indisputable heterogeneity of solid tumors, therefore, compromising the recapitulation of molecular features from parental tumors. Primary cancer cells have emerged as an attractive alternative to commercial cell lines since they can preserve such properties more closely. Here, we provide an overview of the basic concepts underlying generation and characterization of primary cell cultures from tumor samples. We emphasize the advantages and disadvantages of using these types of cancer cell cultures, and we make a comparison with other types of cultures used for personalized therapy. Finally, we consider the use of primary cancer cell cultures in personalized therapy as a means to improve drug response prediction and therapeutic outcomes.
癌症是全球第二大致死原因,占死亡人数的六分之一。因此,迫切需要新的、更有效的治疗方案以及药物筛选方法。自上个世纪以来,永生的“稳定”癌细胞系就被用于评估药物反应,但存在一些缺点。由于长期培养,它们常常积累新的基因畸变,并且缺乏实体瘤无可争议的异质性,因此,影响了对亲本肿瘤分子特征的重现。原代癌细胞已成为商业细胞系的一种有吸引力的替代选择,因为它们能够更紧密地保留这些特性。在这里,我们概述了从肿瘤样本中生成和表征原代细胞培养物的基本概念。我们强调使用这类癌细胞培养物的优缺点,并与用于个性化治疗的其他类型培养物进行比较。最后,我们认为将原代癌细胞培养物用于个性化治疗是改善药物反应预测和治疗结果的一种手段。